These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33394204)

  • 1. Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study.
    Sutton E; Lane JA; Davis M; Walsh EI; Neal DE; Hamdy FC; Mason M; Staffurth J; Martin RM; Metcalfe C; Peters TJ; Donovan JL; Wade J;
    Cancer Causes Control; 2021 Mar; 32(3):261-269. PubMed ID: 33394204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of coping strategies in men receiving radiotherapy and neo-adjuvant androgen deprivation for prostate cancer: a quantitative and qualitative study.
    McSorley O; McCaughan E; Prue G; Parahoo K; Bunting B; O'Sullivan J
    J Adv Nurs; 2014 Mar; 70(3):625-38. PubMed ID: 23919321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
    Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
    Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
    Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.
    Wahlgren T; Nilsson S; Ryberg M; Lennernäs B; Brandberg Y
    Acta Oncol; 2005; 44(6):633-43. PubMed ID: 16165923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
    Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
    JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
    Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
    Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
    Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
    Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors.
    Mantz CA; Nautiyal J; Awan A; Kopnick M; Ray P; Kandel G; Niederberger C; Ignacio L; Dawson E; Fields R; Weichselbaum R; Vijayakumar S
    Cancer J Sci Am; 1999; 5(4):230-6. PubMed ID: 10439169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
    Roach M; Bae K; Speight J; Wolkov HB; Rubin P; Lee RJ; Lawton C; Valicenti R; Grignon D; Pilepich MV
    J Clin Oncol; 2008 Feb; 26(4):585-91. PubMed ID: 18172188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of high dose rate brachytherapy in combination with external beam radiotherapy on men's health-related quality of life and sexual function over a 2 year time span.
    Conaglen HM; de Jong D; Hartopeanu C; Conaglen JV; Tyrie LK
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):197-204. PubMed ID: 23183305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
    Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
    Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in men receiving radiotherapy and neo-adjuvant androgen deprivation for prostate cancer: results from a prospective longitudinal study.
    Mc Caughan E; Mc Sorley O; Prue G; Parahoo K; Bunting B; Sullivan JO; McKenna H
    J Adv Nurs; 2013 Jan; 69(1):53-65. PubMed ID: 22458267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.
    Heesterman BL; Aben KKH; van den Bergh ACM; van der Voort van Zyp JRN; Bokhorst LP
    Urol Oncol; 2024 Aug; 42(8):245.e9-245.e18. PubMed ID: 38724349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
    Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
    N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
    Ito T; Grant L; Duckham BR; Ribbands AJ; Gater A
    Adv Ther; 2018 Dec; 35(12):2186-2200. PubMed ID: 30415297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.